Stage I of Phase II study assessing efficacy, safety and tolerability of barasertib (AZD1152) versus LDAC in elderly AML patients

BACKGROUND: This Phase II study evaluated the efficacy, safety and tolerability of the Aurora B kinase inhibitor barasertib, compared with low-dose cytosine arabinoside (LDAC), in patients aged ≥60 years with acute myeloid leukemia (AML). METHODS: Patients were randomized 2:1 to open-label baraserti...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kantarjian, Hagop M, Martinelli, Giovanni, Jabbour, Elias J, Quintás-Cardama, Alfonso, Ando, Kiyoshi, Bay, Jacques-Olivier, Wei, Andrew, Gröpper, Stefanie, Papayannidis, Cristina, Owen, Kate, Pike, Laura, Schmitt, Nicola, Stockman, Paul K, Giagounidis, Aristoteles
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4132839/
https://ncbi.nlm.nih.gov/pubmed/23605952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28113
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky